Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

IMOL 881, a new trypanocidal compound

L Maes1, E B Songa, R Hamers

  • 1Institute of Molecular Biology, Vrije Universiteit Brussel, St. Genesius-Rode, Belgium.

Acta Tropica
|September 1, 1993
PubMed
Summary

A novel drug, IMOL 881, demonstrates potent trypanocidal activity against multiple trypanosome species. It shows promise for both veterinary and human medicine due to its efficacy and low toxicity, with potential prophylactic benefits.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From microstructure to mechanics: A multi-constituent micro-scale computational model of arterial tissue.

Computers in biology and medicine·2025
Same author

Developmental venous anomalies: benign in nature, potentially debilitating for life.

Acta neurologica Belgica·2025
Same author

Antileishmanial Aminopyrazoles: Studies into Mechanisms and Stability of Experimental Drug Resistance.

Antimicrobial agents and chemotherapy·2020
Same author

Transmission potential of paromomycin-resistant Leishmania infantum and Leishmania donovani.

The Journal of antimicrobial chemotherapy·2019
Same author

Need for sustainable approaches in antileishmanial drug discovery.

Parasitology research·2019
Same author

Immunosuppression of Syrian golden hamsters accelerates relapse but not the emergence of resistance in Leishmania infantum following recurrent miltefosine pressure.

International journal for parasitology. Drugs and drug resistance·2018

Area of Science:

  • Drug discovery and development
  • Parasitology
  • Medicinal chemistry

Background:

  • Trypanosomiasis poses a significant threat to both animal and human health globally.
  • Existing treatments for trypanosomiasis often face challenges with efficacy, toxicity, or resistance.
  • There is a continuous need for novel therapeutic agents to combat various trypanosome infections.

Purpose of the Study:

  • To synthesize and characterize a new drug molecule, IMOL 881.
  • To evaluate the trypanocidal activity of IMOL 881 against key trypanosome species.
  • To assess the therapeutic index and prophylactic potential of IMOL 881.

Main Methods:

  • Synthesis of the novel compound IMOL 881.
  • In vitro and in vivo testing of IMOL 881 against specified trypanosome species.
  • Evaluation of drug toxicity and therapeutic index in animal models.
  • Prophylactic efficacy studies using infected animal models.

Main Results:

  • IMOL 881 exhibited significant trypanocidal activity against Trypanosoma evansi, T. equiperdum, T. gambiense, and T. rhodesiense.
  • The drug demonstrated a high therapeutic index (> 100), indicating a favorable safety profile.
  • IMOL 881 showed promising prophylactic potential in animal models against T. evansi infection.

Conclusions:

  • IMOL 881 represents a potential new therapeutic candidate for treating trypanosomiasis.
  • Its broad-spectrum activity and favorable safety profile warrant further investigation for clinical application.
  • The prophylactic properties of IMOL 881 suggest a dual role in disease management.

Related Experiment Videos